BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (February 2015)

37 slides from BioLineRX's investor presentation, February 2015

  1. Slide 1: Company Presentation

    Slide 1: Company Presentation

    Company Presentation February 2015

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

  3. Slide 3: BioLineRx Snapshot

    Slide 3: BioLineRx Snapshot

    BioLineRx Snapshot • Drug development company focused on oncology & immunology – Founded in 2003 by Teva and other key players in Israeli Life Sciences industry • Bridge “development gap” for Israeli assets – Leverage carefully selected early-stage technology, primarily at academia level, following

  4. Slide 4: Long Term Relationships with Israeli Institutions

    Slide 4: Long Term Relationships with Israeli Institutions

    Long Term Relationships with Israeli Institutions Technion Rambam Medical Center Academic Institutes Haifa Tel Aviv University Medical Centers Sheba Medical Center Tel-Aviv Hebrew University Rehovot Jerusalem Be’er Sheva Hadassah Medical Center Weizmann Institute Ben-Gurion University Sourasky Medic

  5. Slide 5: Main Pipeline Assets

    Slide 5: Main Pipeline Assets

    Main Pipeline Assets Pre-Clinical Phase Ill PROJECT INDICATION LEAD DEVELOPMENT PROGRAMS AML Stem cell mobilization BL-7010 Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS BL-7040 Inflammatory bowel disease BL-9010 Severe asthma/allergies BL-1110 Neuropathic pain/scleroderma PROGRAMS PARTNERED OR IN

  6. Slide 6: Main 2014 Achievements

    Slide 6: Main 2014 Achievements

    Main 2014 Achievements • R&D Achievements in 2014 – All three lead development programs met their objectives in 2014 • BL-8040 (r/r AML) - phase 2 study partial results – Clinical evidence for MOA (mobilization and apoptosis) • BL-7010 (celiac program) - phase 1/2 completion • BL-1040 (AMI) - comple

  7. Slide 7: Main 2015 Value Drivers

    Slide 7: Main 2015 Value Drivers

    Main 2015 Value Drivers • BL-8040 stem cell mobilization study – Top line results by end of Q1 2015 • BL-8040 r/r AML study – Top line results H2 2015 • BL-1040 CE Mark registration study – Topline results mid-year 2015 • BL-7010 project – Final approval of device regulatory path in EU from Notified

  8. Slide 8: Lead Development Programs

    Slide 8: Lead Development Programs

    LEAD DEVELOPMENT PROGRAMS 8

  9. Slide 9: BL-8040: Best-in-Class CXCR4 Antagonist for Hematological Cancers

    Slide 9: BL-8040: Best-in-Class CXCR4 Antagonist for Hematological Cancers

    BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF HEMATOLOGICAL CANCERS 9

  10. Slide 10: BL-8040 Highlights

    Slide 10: BL-8040 Highlights

    BL-8040 Highlights • Platform Molecule: Can Address Multiple Cancer Indications – Acute myeloid leukemia (AML) & other blood cancers – Received Orphan designation from FDA for lead indications (accelerates development) • Mode of Action: Inhibits CXCR4 (a cell surface protein) – Present in high quant

  11. Slide 11: AML – Treatment and Unmet Medical Need

    Slide 11: AML – Treatment and Unmet Medical Need

    AML – Treatment and Unmet Medical Need • AML is most common acute leukemia in adults – Over 60,000 new cases recorded worldwide in 2010, growing to 130,000 by 2020 – 14,000 cases of AML diagnosed in the US in 2012 – Majority of AML patients relapse and require repeated treatment cycles • AML has poo

  12. Slide 12: BL-8040 Mechanism Of Action

    Slide 12: BL-8040 Mechanism Of Action

    BL-8040 Mechanism Of Action • Binds CXCR4 with high affinity (1-2 nM) • Maintains extended inhibition of CXCR4 through long receptor occupancy (>24 hours) • Works as inverse agonist of CXCR4 • Induces apoptosis of tumor cells dependent on CXCR4 for survival • Increases sensitivity to anti-cancer age

  13. Slide 13: BL-8040 Shows Superiority to Current Therapy

    Slide 13: BL-8040 Shows Superiority to Current Therapy

    BL-8040 Shows Superiority to Current Therapy BL-8040 12 mg/kg Mozobil 3.2 mg/kg Number of Neutrophils BL-8040 Stimulates Greater Mobilization of Cells from the Bone Marrow Compared to Mozobil Time post BL-8040/Mozobil injection Abraham M., Stem Cells 2007;25:2158 –2166 Mozobil BL-8040 Causes Signifi

  14. Slide 14: BL-8040 is Best-in-Class vs. Competitors

    Slide 14: BL-8040 is Best-in-Class vs. Competitors

    BL-8040 is Best-in-Class vs. Competitors BMS-936564 BL-8040 Mozobil (MDX1338) Affinity for CXCR4 1-2 nM 84 nM 5nM Inhibition Inverse agonist Antagonist (partial agonist) Antagonist Extracellular domains in the Trans-membrane regions in the Extracellular domains in the CXCR4 Binding site CXCR4 recept

  15. Slide 15: Phase 2a - Treatment of r/r AML patients

    Slide 15: Phase 2a - Treatment of r/r AML patients

    Phase 2a - Treatment of r/r AML patients Open-label study to evaluate safety and efficacy profile of repeated escalating doses of BL-8040 in up to 70 adult subjects with relapsed or refractory AML Study design: – Dose escalation phase – 3+3 design (last update given re 5th cohort of 1.5 mg/kg) – Exp

  16. Slide 16: Partial Results in AML Phase 2 Study

    Slide 16: Partial Results in AML Phase 2 Study

    Partial Results in AML Phase 2 Study • No BL-8040 related SAEs and no AEs were considered DLTs • Robust leukemic blast mobilization was observed (median of 6-fold increase) • BL-8040 monotherapy decreased amount of leukemic cells in BM by median of ~70% • BL-8040 monotherapy achieved 3.5-fold increa

  17. Slide 17: Phase 1 - Single Agent Stem Cell Mobilization

    Slide 17: Phase 1 - Single Agent Stem Cell Mobilization

    Phase 1 - Single Agent Stem Cell Mobilization A Phase 1, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects Study design: • Part 1 – Dose escalation, randomized, placebo controlled - up to 4 escalating doses

  18. Slide 18: Three New Studies to be Initiated in 2015

    Slide 18: Three New Studies to be Initiated in 2015

    Three New Studies to be Initiated in 2015 Results Study Collaborator Description  AML German Study Double-blind, placebo-controlled, Consolidation Alliance Topline results repeated-administration, multi Phase 2b Leukemia Q4 2017 treatment cycles (200 patients) Group Open-label, 2 parts: Partial res

  19. Slide 19: BL-8040 Summary

    Slide 19: BL-8040 Summary

    BL-8040 Summary • CXCR4 is a validated target • BL-8040 has robust mobilization activity and apoptosis – Validated in preliminary data from Phase II study in AML, and Phase 1/2 study in multiple myeloma – BL-8040 has very favorable profile in comparison with leading CXCR4 antagonists • BL-8040 is an

  20. Slide 20: BL-1040: First-in-Class Myocardial Implant for Ventricular Remodeling

    Slide 20: BL-1040: First-in-Class Myocardial Implant for Ventricular Remodeling

    BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI Out-licensed to Bellerophon (f/k/a Ikaria) and being developed as Bioabsorbable Cardiac Matrix (BCM) 20

  21. Slide 21: BL-1040 Highlights

    Slide 21: BL-1040 Highlights

    BL-1040 Highlights • Indication: Cardiac remodeling post-AMI • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial – enrollment completed; top-line results in mid-2015 • Device designation (including FDA) • Partnered with Bellerophon BCM (f/k/a Ika

  22. Slide 22: Unmet Medical Need

    Slide 22: Unmet Medical Need

    Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 22

  23. Slide 23: How Does BL-1040 Work?

    Slide 23: How Does BL-1040 Work?

    How Does BL-1040 Work? Porcine AMI model, day 60 Arterial injection deposits Untreated BL-1040 material into infarcted tissue L L Turns from liquid to gel on V V contact with infarcted tissue Gel-like scaffold provides mechanical support to damaged tissue • Dilated • Normal size • Thin LV wall • Nor

  24. Slide 24: BL-1040 Clinical studies

    Slide 24: BL-1040 Clinical studies

    BL-1040 Clinical studies Pilot study in Europe  • Enrollment of 27 patients with primary MI at high risk for LV remodeling; six-month follow-up • 9 sites: 6 in Germany, 3 in Belgium • Excellent safety results; signs of preliminary efficacy in patients Pivotal CE Mark Registration trial progressing

  25. Slide 25: BL-1040 Summary

    Slide 25: BL-1040 Summary

    BL-1040 Summary • Huge unmet medical need – >$1 billion market • Designated as device in both US and Europe • Pilot study successfully completed – No safety or tolerability issues after six months of follow-up – Promising efficacy in comparison to historical data • Top-line results of CE mark regist

  26. Slide 26: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    Slide 26: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 26

  27. Slide 27: BL-7010: Polymeric Binder for Celiac Disease

    Slide 27: BL-7010: Polymeric Binder for Celiac Disease

    BL-7010: Polymeric Binder for Celiac Disease • Indication: Celiac disease • Mode of Action: Non-absorbable polymer with high affinity to gliadins (immunogenic peptides contained in gluten) • Status: Phase 1/2 completed • Product Highlights – Prevents pathological damage to small intestine – Non-abso

  28. Slide 28: Celiac Disease – Large Unmet Medical Need

    Slide 28: Celiac Disease – Large Unmet Medical Need

    Celiac Disease – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option is life-lo

  29. Slide 29: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    Slide 29: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

  30. Slide 30: BL-7010 Maintains Normal Structure of GI

    Slide 30: BL-7010 Maintains Normal Structure of GI

    BL-7010 Maintains Normal Structure of GI Model: HLA-DQ8/HCD4 transgenic male mice sensitized to gliadin non-sensitized Gluten-sensitized Gluten-sensitized mice mice mice + BL-7010 Villus-to-crypt ratio 5.96 ± 1.23 2.58 ± 0.43 4.89 ± 1.51 30

  31. Slide 31: BL-7010 Clinical Program Overview

    Slide 31: BL-7010 Clinical Program Overview

    BL-7010 Clinical Program Overview • Phase 1/2 study in celiac patients completed – Consisted of 2 parts: – Single ascending dose – 14 days repeated administration – Safety endpoints – 3 times per day – No efficacy endpoints – Safety w/o efficacy endpoints – Assessment of systemic exposure – Assessme

  32. Slide 32: BL-7010 Summary

    Slide 32: BL-7010 Summary

    BL-7010 Summary • Celiac disease is huge unmet medical need – There are only a handful of clinical-stage programs in development • BL-7010 has unique and simple MOA • Successful Phase 1/2 pilot study – Well tolerated, no systemic exposure – Will likely be classified as medical device in Europe • Piv

  33. Slide 33: Corporate

    Slide 33: Corporate

    CORPORATE 33

  34. Slide 34: Transformative Collaboration with Novartis

    Slide 34: Transformative Collaboration with Novartis

    Transformative Collaboration with Novartis • Novartis selected BioLineRx as its leading partner for identification and early development of Israeli-sourced drug candidates – Exclusive first look at all Israeli-based projects scouted by BioLineRx – Co-develop selected projects through clinical proof-

  35. Slide 35: Financial and Corporate Summary

    Slide 35: Financial and Corporate Summary

    Financial and Corporate Summary Cash position • $29.6 million as of September 30, 2014 – Does not include $10 million received from Novartis in December • Funds operational capital through 2016 Capital structure • Traded on NASDAQ and TASE (Symbol: BLRX) • 39 million shares outstanding; 45 million f

  36. Slide 36: Major Development Milestones – 2015 and 2016

    Slide 36: Major Development Milestones – 2015 and 2016

    Major Development Milestones – 2015 and 2016 BL-1040 (AMI) complete CE mark study enrollment √ BL-8040 (SC Mobilization) phase 1 completion √ BL-8040 (Consolidation) phase 2b initiation BL-8040 (AML) phase 2 partial results* BL-8040 (FLT-3) phase 1/2 initiation BL-8040 (SC Mobilization) phase 1 aphe

  37. Slide 37: Bench1o Bedoideto Patner

    Slide 37: Bench1o Bedoideto Patner

    Bench1o Bedoideto Patner BIOLINEM >< 37

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks